NLS Pharmaceutics AG
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 57.09 | -100% | -2.6 | -100% |
| P/S |
|
0 | 33.5 | -100% |
|
|
| P/BV |
|
-77.55 | 4.61 | -1780.68% |
|
|
| P/FCF |
|
0 | 39.71 | -100% |
|
|
| Ev/Ebitda |
|
-58.14 | -19.46 | 198.82% |
|
|
| Ev/S |
|
0 | 22.56 | -100% |
|
|
| Ev/FCF |
|
-70.81 | 45.47 | -255.73% |
|
|
| E/P |
|
0 | 0.0164 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -14.42 | -100% | 0 | 0% |
| ROE |
|
137.79 | 9.01 | 1429.27% |
|
|
| ROA |
|
-659.14 | 0.0151 | -4352399.51% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -26.5 | -100% |
|
|
| ROCE |
|
133.66 | 13.75 | 871.86% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.1385 | -3.73 | -96.29% | -0.3046 | -54.52% |
| Nеt Debt/Ebitda |
|
-0.0624 | -3.19 | -98.05% |
|
|
| Debt/Ratio |
|
0.8847 | 0.1777 | 397.81% |
|
|
| Debt/Equity |
|
0 | 1.57 | -100% |
|
|
| Debt/Net Income |
|
-0.1342 | 0.8429 | -115.92% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5467 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2387 | -100% |
|
|
| Average dividend growth |
|
0 | 1.55 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4967 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.73 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5467 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 73.67 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
174.32 | 15.28 | 1040.84% | ||
| Growth impulse Net Income in 5 years |
|
106.31 | -33.08 | -421.37% | ||
| Growth impulse FCF in 5 years |
|
4997.09 | -6.99 | -71589.13% | ||
| Growth impulse EPS in 5 years |
|
-36.1 | -59.11 | -38.93% |
IP Score
3.93/10
